Related Experiment Videos
[Long-term experiences with moxonidine, a new antihypertensive agent]
Fortschritte Der Medizin
|November 10, 1990
Summary
Monoxidine effectively lowers blood pressure in hypertensive patients by stimulating alpha-2-receptors. This new antihypertensive agent demonstrated good tolerability and safety over 12 months of treatment.
Area of Science:
- Pharmacology
- Cardiovascular Medicine
- Clinical Trials
Background:
- Hypertension remains a significant global health concern, necessitating novel therapeutic agents.
- Monoxidine is a novel antihypertensive agent targeting central presynaptic alpha-2-receptors.
Purpose of the Study:
- To evaluate the efficacy and safety of monoxidine in the long-term treatment of ambulatory hypertensives.
- To assess blood pressure reduction and tolerability over a 12-month treatment period.
Main Methods:
- An open-label, multicenter trial involving 141 ambulatory hypertensive patients.
- A 12-month treatment period with monoxidine, including an initial dose-adjustment phase.
- Monitoring of supine blood pressure, drug tolerance, and adverse events.
Main Results:
- Monoxidine significantly reduced mean supine blood pressure from 172.7/103.2 mmHg to 150.7/87.5 mmHg within 3 weeks.
- 96 patients achieved target blood pressure with 0.2 mg daily, while 52 required 0.4 mg.
- No tolerance developed over 12 months; 97% of patients tolerated the drug well, with dry mouth and lassitude as main side effects.
Conclusions:
- Monoxidine is a well-tolerated, reliable, and safe antihypertensive agent for long-term use.
- The drug's efficacy in reducing blood pressure was sustained throughout the 12-month treatment period.
- Gradual increase in blood pressure upon discontinuation suggests sustained pharmacological effect.